AI in Healthcare & Science · AI in Clinical Trials

What Are the Risks of Using AI in Clinical Trial Design?

Key risks of using AI in clinical trial design include the potential for biased or unrepresentative training data to skew patient selection or endpoints, over-reliance on AI-identified patterns that don't hold up in practice, and reduced transparency if AI-driven design choices aren't clearly documented and explainable to regulators and researchers.

Medical disclaimer

This page is for general educational purposes only and is not medical advice. It does not replace a consultation with a licensed physician, pharmacist, or other qualified health provider. Always talk to your own care team before starting, stopping, or changing any medication or supplement.

Key takeaways

If the historical data used to train an AI tool underrepresents certain populations, AI-informed trial design decisions could unintentionally reinforce those same gaps.
Overreliance on AI-identified patient subgroups or endpoints without sufficient independent scientific validation is a recognized concern among researchers.
A lack of transparency about how an AI system arrived at a particular design recommendation can complicate regulatory review and scientific scrutiny.
Trial design errors introduced by flawed AI input could affect the validity or generalizability of a trial's eventual results.
Regulatory bodies have been developing guidance on the appropriate use of AI tools in the drug development and clinical trial process.

Data Bias Can Quietly Shape Trial Design

One of the most significant recognized risks of using AI in clinical trial design is that these tools learn from existing historical data, and that data can carry its own gaps and biases. If certain populations — based on factors like race, sex, age, or socioeconomic background — have historically been underrepresented in the medical data an AI tool was trained on, decisions the tool informs, such as which patient subgroups to prioritize or which endpoints to focus on, could unintentionally reflect or even reinforce those same historical gaps. This is a particularly consequential risk in clinical trials, where the entire goal is to generate evidence that’s meaningfully generalizable to the real patient population who will eventually use a treatment.

This risk isn’t unique to AI — human-designed trials have historically faced similar representativeness challenges — but AI can scale and embed these patterns more systematically if not carefully checked, which is why researchers and regulators have paid particular attention to this issue as AI’s role in trial design has grown.

Overreliance on Unvalidated Patterns

A second category of risk involves trusting AI-identified patterns — such as a proposed patient subgroup likely to respond well to a treatment, or a suggested trial endpoint — without sufficient independent scientific scrutiny. AI models can identify statistical patterns in data that don’t necessarily reflect a genuine underlying biological relationship; sometimes a pattern is a coincidence or an artifact of how the training data was collected rather than a real, reproducible effect. If trial designers lean too heavily on an AI-suggested pattern without adequately validating it through established scientific methods, it could lead to a trial design that’s less scientifically sound than intended, potentially affecting the trial’s outcomes or its ability to produce meaningful, actionable results.

Transparency and Regulatory Scrutiny

Clinical trial design decisions need to be explainable and defensible to ethics review boards, regulators, and the broader scientific community. If an AI system’s specific recommendations aren’t clearly documented or aren’t reasonably interpretable, it can become harder for these stakeholders to evaluate whether a particular design choice was scientifically justified. This has prompted regulators, including the FDA, to develop evolving guidance around the appropriate and transparent use of AI tools throughout the drug development process, reflecting an active, ongoing effort to manage these risks as the technology becomes more embedded in clinical research practice.

Bottom Line

Using AI in clinical trial design carries real risks, including the potential for biased training data to skew patient selection, overreliance on statistically identified but scientifically unvalidated patterns, and reduced transparency in how design decisions are made — risks that researchers and regulators are actively working to address as the technology matures.

Go deeper

Important caveats

These are recognized categories of risk being actively discussed by researchers and regulators, not a claim that every AI-assisted trial has these problems.
Mitigation approaches, such as rigorous validation and transparency requirements, continue to evolve alongside the technology itself.

Frequently asked questions

Can biased data lead to a poorly designed clinical trial?

Yes, this is a recognized risk. If the data used to train an AI tool involved in trial design underrepresents certain populations or contains other biases, decisions informed by that tool — such as which patient subgroups to focus on — could unintentionally reflect or reinforce those same gaps, potentially affecting how generalizable the trial's results are.

Do regulators have specific guidance on AI use in clinical trials?

Regulatory bodies including the FDA have been actively developing and updating guidance related to the use of AI and machine learning throughout drug development, including clinical trial design and conduct, reflecting the recognition that this is a fast-evolving area requiring ongoing regulatory attention.

Why does transparency matter when AI informs trial design decisions?

Clinical trial design choices need to be scientifically justifiable and open to scrutiny by researchers, ethics review boards, and regulators. If an AI system's recommendations aren't well understood or documented, it can be harder to evaluate whether a given design decision is scientifically sound, which is why explainability is an active area of focus in this space.

Sources

[1]U.S. Food and Drug Administration — U.S. Food and Drug Administration
[2]National Institutes of Health — National Institutes of Health

Written by Editorial Team

Last updated July 25, 2026

Get one well-sourced answer a week

No spam. Unsubscribe anytime.